Adaptive Biotechnologies Corporation
ADPT
$16.80
-$0.10-0.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.88M | 52.44M | 47.46M | 46.44M | 43.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.88M | 52.44M | 47.46M | 46.44M | 43.19M |
| Cost of Revenue | 42.13M | 16.98M | -44.64M | 40.83M | 44.67M |
| Gross Profit | 16.75M | 35.46M | 92.09M | 5.61M | -1.48M |
| SG&A Expenses | 41.36M | 40.45M | 39.63M | 37.81M | 38.21M |
| Depreciation & Amortization | 423.00K | 419.00K | 428.00K | 428.00K | 424.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.92M | 82.05M | 81.30M | 79.07M | 83.30M |
| Operating Income | -25.04M | -29.60M | -33.84M | -32.63M | -40.11M |
| Income Before Tax | -25.59M | -29.83M | -33.72M | -32.10M | -46.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.59M | -29.83M | -33.72M | -32.10M | -46.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -21.00K | -22.00K | 25.00K | 26.00K | 26.00K |
| Net Income | -25.61M | -29.85M | -33.69M | -32.07M | -46.22M |
| EBIT | -25.04M | -29.60M | -33.84M | -32.63M | -40.11M |
| EBITDA | -20.53M | -24.87M | -29.39M | -28.04M | -35.11M |
| EPS Basic | -0.17 | -0.20 | -0.23 | -0.22 | -0.31 |
| Normalized Basic EPS | -0.11 | -0.13 | -0.15 | -0.14 | -0.17 |
| EPS Diluted | -0.17 | -0.20 | -0.23 | -0.22 | -0.31 |
| Normalized Diluted EPS | -0.11 | -0.13 | -0.15 | -0.14 | -0.17 |
| Average Basic Shares Outstanding | 152.08M | 149.20M | 147.68M | 147.52M | 147.41M |
| Average Diluted Shares Outstanding | 152.08M | 149.20M | 147.68M | 147.52M | 147.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |